Trinity Biotech plc (TRIB) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Trinity Biotech plc (TRIB) Healthcare & Pipeline Overview

Trinity Biotech plc, headquartered in Ireland, specializes in medical diagnostic solutions for clinical and point-of-care applications, focusing on infectious disease and diabetes testing. With a global presence, the company serves public health authorities, clinical laboratories, and research institutes through direct sales and strategic partnerships.

What Is the Investment Thesis for TRIB?

Trinity Biotech plc operates in the medical diagnostics market, which is characterized by ongoing demand for infectious disease testing and diabetes monitoring solutions. The company's global presence and diverse product portfolio offer potential for revenue growth. However, the company's negative profit margin of -75.9% and negative P/E ratio of -0.38 indicate financial challenges. Investors should carefully consider the company's ability to improve profitability and manage its debt. Upcoming catalysts include potential new product launches and expansion into new geographic markets. The company's beta of 0.70 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

TRIB Key Highlights

Market capitalization of $214M indicates a small-cap company.

• Gross margin of 34.7% reflects the profitability of Trinity Biotech's products after accounting for the cost of goods sold.
• Negative profit margin of -75.9% highlights significant challenges in achieving overall profitability.
• Beta of 0.70 suggests lower volatility compared to the broader market.
• The company operates in the growing medical diagnostics market, driven by increasing demand for diagnostic testing.

Who Are TRIB's Competitors?

TRIB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TRIB's Key Strengths?

Diverse product portfolio in diagnostics.

• Global distribution network.
• Expertise in immunoassay development.
• Established relationships with public health authorities and NGOs.

What Are TRIB's Weaknesses?

Negative profit margin.

• High debt levels.
• Limited brand recognition compared to larger competitors.
• Dependence on key distributors.

What Could Drive TRIB Stock Higher?

Potential new product launches in the infectious disease diagnostics segment.

• Expansion of distribution network in emerging markets.
• Development of new diagnostic assays for unmet medical needs.
• Strategic partnerships with other diagnostic companies.
• Increasing demand for diabetes management solutions.

What Are the Key Risks for TRIB?

Financial-distress signal — its Altman Z-Score of -1.85 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Intense competition from larger diagnostic companies.
• Regulatory changes and compliance requirements.
• Technological obsolescence.
• Negative profit margin and high debt levels.
• Economic downturns affecting healthcare spending.

What Are the Growth Opportunities for TRIB?

• Expansion in Point-of-Care (POC) Testing: The POC diagnostics market is experiencing rapid growth due to its ability to deliver quick results and improve patient outcomes. Trinity Biotech can capitalize on this trend by expanding its POC product offerings and distribution channels. The global POC diagnostics market is projected to reach $49.1 billion by 2027, offering a substantial growth opportunity for Trinity Biotech. Timeline: Ongoing.
• Geographic Expansion in Emerging Markets: Emerging markets in Asia and Africa present significant growth opportunities for Trinity Biotech due to increasing healthcare expenditure and rising awareness of diagnostic testing. By expanding its presence in these regions, Trinity Biotech can tap into new customer segments and increase its revenue base. The emerging markets diagnostics market is expected to grow at a CAGR of 8-10% over the next five years. Timeline: Ongoing.
• Development of Novel Diagnostic Assays: Investing in research and development to create innovative diagnostic assays for emerging diseases and unmet medical needs can drive future growth for Trinity Biotech. By developing proprietary technologies and products, the company can differentiate itself from competitors and capture a larger share of the market. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: Forming strategic partnerships with other diagnostic companies or acquiring complementary businesses can expand Trinity Biotech's product portfolio and market reach. By collaborating with other players in the industry, the company can leverage synergies and accelerate its growth. Timeline: Ongoing.
• Focus on Diabetes Management Solutions: With the global prevalence of diabetes on the rise, there is a growing demand for effective diabetes management solutions. Trinity Biotech can capitalize on this trend by developing and marketing innovative products for diabetes monitoring and diagnosis. The global diabetes care devices market is projected to reach $30.7 billion by 2027. Timeline: Ongoing.

What Are TRIB's Competitive Advantages?

• Established presence in the medical diagnostics market.
• Diverse product portfolio targeting multiple disease areas.
• Global distribution network.
• Expertise in immunoassay development and manufacturing.

What Does TRIB Do?

Trinity Biotech plc, established in 1992 and based in Bray, Ireland, is a global diagnostics company focused on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care (POC) segments of the diagnostic market across the Americas, Africa, Asia, and Europe. Trinity Biotech's product portfolio includes a range of diagnostic tests and instrumentation designed to detect infectious diseases, such as Lyme disease, sexually transmitted diseases (syphilis and herpes), SARS-CoV-2, and other viral pathogens like Epstein-Barr and measles. Additionally, the company offers products for in-vitro diagnostic testing for hemoglobin A1c, used in diabetes monitoring and diagnosis. Trinity Biotech also develops and sells products in various immunoassay formats, including immunofluorescence assay, enzyme-linked immunosorbent assay, western blot, and line immunoassay. Furthermore, the company provides reagent products for the diagnosis of liver and kidney diseases, as well as hemolytic anemia. Trinity Biotech serves public health authorities, non-governmental organizations, and clinical and reference laboratories through its direct sales force and a network of independent distributors and strategic partners.

What Products and Services Does TRIB Offer?

• Develops and manufactures medical diagnostic products.
• Offers diagnostic tests for infectious diseases like Lyme disease and SARS-CoV-2.
• Provides products for diabetes monitoring through hemoglobin A1c testing.
• Sells immunoassay products in various formats, including ELISA and Western blot.
• Offers reagent products for diagnosing liver, kidney diseases, and hemolytic anemia.
• Sells raw materials to life sciences industry and research institutes.
• Serves public health authorities, NGOs, and clinical laboratories.

How Does TRIB Make Money?

• Develops and manufactures diagnostic products.
• Sells products through direct sales force and distributors.
• Generates revenue from sales of diagnostic tests and instrumentation.
• Provides products for both clinical laboratory and point-of-care segments.

What Industry Does TRIB Operate In?

Trinity Biotech plc operates within the medical diagnostics industry, a sector characterized by continuous innovation and increasing demand for accurate and rapid diagnostic solutions. The global medical diagnostics market is driven by factors such as the rising prevalence of infectious diseases, the growing aging population, and the increasing adoption of point-of-care testing. The industry is competitive, with key players including ADVB, BGLC, CHEK, EVGN, and GBS. Trinity Biotech competes by offering a range of diagnostic tests and instrumentation for infectious diseases and diabetes monitoring.

Who Are TRIB's Key Customers?

• Public health authorities
• Non-governmental organizations
• Clinical and reference laboratories
• Research institutes

Wall Street analysts project Trinity Biotech plc revenue of about $59.5M for fiscal 2026, with EPS near $-32.70.

Quarterly Financial Performance: Trinity Biotech plc

Revenue for Trinity Biotech plc came in at $11.1M during Q4 2025, a 22.3% contraction versus the preceding quarter. The company recorded a net loss of $17.5M, with diluted EPS of $-28.20. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, TRIB averaged $-15.15 in diluted EPS.

TRIB Valuation & Market Position

With a $214M market cap, Trinity Biotech plc sits in the micro-cap segment of the market. Relative to its peer group, TRIB's quantitative score of 47/100 is below the peer average of 58/100.

Return on equity for Trinity Biotech plc stands at 68.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.25 means current liabilities exceed short-term assets, a liquidity point worth watching.

Trinity Biotech plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.85 places it in the distress zone, a signal of elevated financial risk.

Trinity Biotech plc has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 32.1% below estimates on average.

Company Profile

Trinity Biotech plc operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Bray, IE. The company is led by CEO John Gillard. TRIB has traded publicly since 1992.

TRIB Financials

TRIB Latest News

TRIB Analyst Consensus

TRIB MoonshotScore

Trinity Biotech plc Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources